Sustained-Release Zonisamide Composition for Short GI Transit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sustained-release formulations for antiepileptic drugs like zonisamide in animals, particularly dogs and cats, face challenges in maintaining a controlled release rate due to their short gastrointestinal tracts, leading to burst-like releases or delayed release rates, making twice-daily administration necessary.
Innovation Solution
A composition comprising zonisamide, sugar, wax, and water-soluble polymer that achieves pseudo zero-order release, ensuring consistent drug dissolution over a short period without burst-like or delayed release, allowing once-daily administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a general sustained-release formulation is used, then the drug release is extended over time, but the formulation is excreted before complete drug release due to short gastrointestinal tract, resulting in poor bioavailability
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using amorphous zonisamide mixed with specific excipients (mannitol, hydrogenated castor oil, gum arabic) to achieve rapid dissolution within 3 hours, matching the transit time through the dog's gastrointestinal tract while maintaining sustained-release properties
Solution Approach 2:
The patent creates a composite formulation combining amorphous zonisamide with multiple excipients (mannitol as filler, hydrogenated castor oil as lubricant, gum arabic as binder) to achieve both rapid initial dissolution and controlled sustained release, resolving the contradiction between release duration and bioavailability
2Reliability
If a fast release rate sustained-release formulation is used to improve bioavailability, then the drug dissolves quickly, but the release rate cannot be controlled and becomes burst-like, similar to normal formulations
Solution Approach 1:
The patent uses amorphous zonisamide (changed physical state from crystalline) which inherently provides rapid dissolution, while the combination with specific excipients in controlled ratios maintains release rate control, achieving both high bioavailability and controlled release without burst effect
Solution Approach 2:
The excipients (mannitol, hydrogenated castor oil, gum arabic) act as intermediaries that moderate the release of amorphous zonisamide, preventing burst release while maintaining rapid dissolution and controlled sustained-release profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains a constant drug release rate, completing dissolution within a given time frame, independent of time course, and can be tailored for different animal types by adjusting ingredient composition and ratios, ensuring effective bioavailability and compliance.
Implementation Method 1
a water-soluble polymer... can complete the dissolution of the whole of the drug within a given short time in pseudo zero-order release pattern
Implementation Method 2
The composition of the present invention does not produce a burst-like release in early dissolution and does not create a delay in late dissolution
Implementation Method 3
a drug composition comprising zonisamide, a sugar, a wax, and a water-soluble polymer can complete the dissolution of the whole of the drug
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.